· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2013 / N 1 Возможности коррекции сердечно-сосудистого риска у больных ХОБЛ (список литературы) А.В. Мелехов, Е.Е. Рязанцева Список литературы 1. Life in the 21st century: a vision for all. Geneva, Switzerland: World Health Organization, 1998 2. Giovino GA. The tobacco epidemic in the United States. Am J Prev Med. 2007;33(6 Suppl):S318–26. 3. Sin DD, Man SF. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol. 2005;83(1):8–13. 4. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax. 2008;63(7):599–605. 5. Rodriguez-Roisin R, Soriano JB. Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease. Proceedings of the American Thoracic Society. 2008;5(8):842–7. 6. Agusti A, Soriano JB. COPD as a systemic disease. COPD. 2008;5(2):133–8. 7. GOLD. Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2007 http://www.goldcopd.org/Guidelineitem.asp?l1 = 2&l2 = 1&intId = 996. 8. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61(1):23–8. 9. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107(3):363–9. 10. Haider AW, Larson MG, O’Donnell CJ, et al. The association of chronic cough with the risk of myocardial infarction: the Framingham Heart Study. Am J Med 1999; 106:279–284. 11. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348:567–572. 12. Ebi-Kryston KL. Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study. J Clin Epidemiol 1998; 41:251–260. 13. Zureik M, Kauffmann F, Touboul PJ, et al. Association between peak expiratory flow and the development of carotid atherosclerotic plaques. Arch Intern Med 2001; 161:1669–1676. 14. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8(9):651–745. 15. Tillie-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, Tonnel AB, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med. 2006;144(6):390–6. 16. Erelel M, Cuhadaroglu C, Ece T, Arseven O. The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2002;96(7):515–8. 17. Salisbury AC, Reid KJ, Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol. 2007;99(5):636–41. 18. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313 (7059): 711–5; discussion 15–6. 19. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128(4):2640–6. 20. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? a multiple cause coding analysis. Eur Respir J. 2003;22(5):809–14. 21. Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol (2010) 25:253–260. 22. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a metaanalysis. Chest. 2004;125(6):2309–21. 23. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, McMurray JJ. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol. 2011 May 24;57(21):2127-38. 24. de Vries F, Pouwels S, Bracke M, Lammers JW, Klungel O, Leufkens H, van Staa T. Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension. Br J Clin Pharmacol. 2008 Apr;65(4):580-6 25. Mentz RJ, Fiuzat M, Kraft M, Lindenfeld J, O'Connor CM. Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? J Card Fail. 2012 May;18(5):413-22. 26. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43(12): 1603–11. 27. Suissa S, Hemmelgarn B, Blais L, et al. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996;154:1598–1602. 28. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000;16:505–511. 29. Mairesse S, Blacher J, Safar ME. Focus on beta-blockers for vascular specialists in 2012. Journal des maladies vasculaires, 2011. 36(6): p. 339-47. 30. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJV. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009 February; 11(2): 130–139. 31. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007 Jan 16;49(2):171-80. 32. Foresi A, Cavigioli G, Signorelli G, Pozzoni MB, Olivieri D. Is the use of beta-blockers in COPD still an unresolved dilemma? Respiration. 2010;80(3):177-87. 33. Brodde O. The pharmacology of bisoprolol. Rev Contemp Pharmacother 1997;8:21–33. 34. Short, P.M. et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ, 2011.342:p.d2549. 35. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010 May 24;170(10):880-7. 36. Agostoni P, Contini M, Cattadori G et al. Lung function with carvedilol and bisoprolol in CHF: is beta selectivity relevant? Eur J Heart Fail 2007;9;827-33. 37. Мелехов А.В. Состояние артериального сосудистого русла, микроциркуляции и биомеханики дыхания у больных с хронической сердечной недостаточностью. Диссертация канд. мед. наук. Москва, 2005. 38. Национальные рекомендации ВНОК ИОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. Том 11, №1(57), 2010г. 39. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010 Apr 27;55(17):1780-7. 40. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, McMurray JJ. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009 Jul;11(7):684-90. 41. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011 Oct;105 Suppl 1:S44-9. 42. Düngen HD, Apostolovic S, Inkrot S, Tahirovic E, Töpper A, Mehrhof F, Prettin C, Putnikovic B, Neskovic AN, Krotin M, Sakac D, Lainscak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, Doehner W, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich G, Dietz R; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011 Jun;13(6):670-80. 43. Григорьева Н.Ю., Шарабрин Е.Г., Кузнецов А.Н. Сравнение клинической эффективности оригинального препарата бисопролола и его дженерика у больных стабильной стенокардией в сочетании с хронической обструктивной болезнью легких. Рациональная фармакотерапия в кардиологии, 2010;6(4):497-501.    [ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]